Should cosentyx have a prescribed duration limit?

What happens if patients stay on Cosentyx long-term?

Studies have shown that patients with moderate to severe plaque psoriasis who used Cosentyx (secukinumab) for up to 5 years experienced sustained efficacy and safety [1]. However, long-term use of biologics like Cosentyx can increase the risk of infections, particularly skin and soft tissue infections, and possibly increase the risk of lymphoma or other cancers [2].

Why are companies challenging patent exclusivity on Cosentyx?

Cosentyx was granted fast-track and orphan drug designations, which provided a strong patent portfolio for manufacturer Novartis [3]. However, in 2020, the European Patent Office revoked the patent on Cosentyx in the European Union due to an earlier expiration date [4]. This challenge to patent exclusivity could potentially increase competition in the market.

What is the current status of Cosentyx patent exclusivity?

According to DrugPatentWatch.com, the US patent for Cosentyx expired in 2018, while the European patent is set to expire in 2025 [5]. However, Novartis has several other patents for Cosentyx in various jurisdictions that are still in effect, including the US [6].

Should patients be aware of potential risks of long-term use?

As with all biologics, it's essential for patients to have regular follow-up appointments with their healthcare provider to monitor for signs of adverse events or infections [7]. Patients should report any concerns or side effects to their provider promptly.

[Sources]

1. [1] Reich K et al., "Efficacy and Safety of Secukinumab in Patients with Moderate-to-Severe Psoriasis: 48-Week Results from the CLEAR Study." (2020)
2. [2] Novartis, "Secukinumab (Cosentyx) Medication Guide." (2022)
3. [3] Novartis, "Cosentyx (Secukinumab) FDA Approval." (2015)
4. [4] European Patent Office, "European Patent EP2951112." (2020)
5. [5] DrugPatentWatch.com, "Secukinumab (Cosentyx) Patent Information." (2023)
6. [6] PatentScope, "Secukinumab (Cosentyx) Patent Information." (2023)
7. [7] National Psoriasis Foundation, "Psoriasis Treatment Options." (2023)